Login to Your Account



CRL hits Lilly/Incyte on baricitinib, wants more data on dose

By Randy Osborne
Staff Writer

Friday, April 14, 2017

Bad news came on Good Friday for Incyte Corp. and Eli Lilly and Co. in the form of a CRL from the FDA related to once-daily, oral baricitinib for moderate to severe RA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription